Study to Determine if BHV-1300 is Effective and Safe in Adults With Graves' Disease
Part of paid clinical trials in Burbank, California.
- Sponsor
- Biohaven Therapeutics Ltd.
- Study ID
- NCT07661056
- Phase
- PHASE3
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 70 Years
- Healthy Volunteers
- Not accepted
Interventions
- BHV-1300 — DRUGdelivered subcutaneously via autoinjector
- Placebo — DRUGdelivered subcutaneously via autoinjector
Study Details
The purpose of this study is to evaluate the efficacy and safety of BHV-1300 in adult participants with Graves' disease who are actively hyperthyroid
Key Dates
- First listed
- Jun 22, 2026
- Start date
- Jun 26, 2026
- Status verified
- Jul 2026
- Primary completion
- Jan 31, 2028
- Completion
- Feb 29, 2028
Study Design
- Enrollment
- 300 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: BHV-1300BHV-1300 is delivered subcutaneously via autoinjector. Participants will be randomized in a 2:1 ratio to receive either BHV-1300 or placebo.
- Placebo Comparator: PlaceboMatching placebo is delivered subcutaneously via autoinjector. Participants will be randomized in a 2:1 ratio to receive either BHV-1300 or placebo.
Primary Outcome Measure
Number of participants on BHV-1300 vs placebo who are not on an antithyroid drug and with normal thyroid function (total T3, free T4 (FT4), & TSH within normal limits) at Week 26. [ Time Frame: Week 26 ]
Central Contacts
- Chief Medical Officer203-404-0410
Locations (24)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Site-032 | Burbank | California | 91501 | - |
| Site-062 | Huntington Beach | California | 92647 | - |
| Site-006 | San Diego | California | 92108 | - |
| Site-067 | Walnut Creek | California | 94598 | - |
| Site-052 | Doral | Florida | 33172 | - |
| Site-019 | Hialeah | Florida | 33016 | - |
| Site-031 | Champaign | Illinois | 61822 | - |
| Site-025 | Lenexa | Kansas | 66234 | - |
| Site-072 | Las Vegas | Nevada | 89148 | - |
| Site-038 | Asheville | North Carolina | 28803 | - |
| Site-011 | Greenville | North Carolina | 27834 | - |
| Site-064 | Morehead City | North Carolina | 28557 | - |
| Site-039 | Raleigh | North Carolina | 27612 | - |
| Site-033 | Statesville | North Carolina | 28625 | - |
| Site-045 | Wilmington | North Carolina | 28405 | - |
| Site-008 | Canton | Ohio | 44718 | - |
| Site-055 | Dallas | Texas | 75231 | - |
| Site-043 | Denton | Texas | 76210 | - |
| Site-042 | El Paso | Texas | 79935 | - |
| Site-071 | Houston | Texas | 77058 | - |
| Site-054 | McKinney | Texas | 75069 | - |
| Site-013 | Layton | Utah | 84041 | - |
| Site-073 | Midlothian | Virginia | 23112 | - |
| Site-076 | Seattle | Washington | 98104 | - |
Related Studies
- Study of BHV-1300 in Graves' DiseasePHASE1 · Recruiting · Biohaven Therapeutics Ltd. · South Gate, California
- Evaluating an AI Tool for Detecting Thyrotoxic StatesRecruiting · THYROSCOPE INC. · San Francisco, California
- NEXUS Study: A Study to Test Single and Multiple Doses of MER511 Given to Adults With Graves' DiseasePHASE1 · Recruiting · Merida Biosciences · Hollywood, Florida
- Telehealth Music Therapy for Adults With Endocrine Disorder and DepressionRecruiting · Appalachian State University · Boone, North Carolina